Interesting - If Remestemcel-L has greater efficacy in COVID-19 ARDS than Ruxolitinib it ‘could’ be viewed by some as a sneak peak at the expected preliminary result of the eventual GVHD results in adults in the confirmatory trial comparing the two, especially due to the similarities like cytokine storms, etc etc ?
Thanks for the article @cindyc
GLTAH
Cell Therapy News/Articles, page-7928
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.35 |
Change
0.020(1.50%) |
Mkt cap ! $1.541B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.40 | $1.34 | $3.562M | 2.615M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.35 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.36 | 17969 | 2 |
View Market Depth
| Last trade - 16.10pm 07/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |